Ocugen GA Trial Advances Toward Phase 3 - Summary - MDSpire
Clinical Guidelines

Ocugen GA Trial Advances Toward Phase 3

Ocugen reports positive Phase 2 data for its OCU410 gene therapy in geographic atrophy

  • May 1, 2026

  • 3 min

Share

Ocugen has reported positive results from its phase 2 ArMaDa clinical trial of OCU410, a novel gene therapy for geographic atrophy (GA) linked to dry age-related macular degeneration (dAMD). The therapy met its primary endpoint, showing a significant 31% reduction in GA lesion growth over 12 months compared to control, which surpasses existing therapies. With no serious adverse events noted, OCU410's one-time subretinal injection could address unmet needs in GA treatment and reduce the burden of frequent injections. A phase 3 study is expected in 2026.

Original Source(s)

Ocugen GA Trial Advances Toward Phase 3

  • May 1, 2026

Related Content

GA Gene Therapy Interest Increases

Phase I trial results of PulseSight Therapeutics’ PST-611 to be presented at ARVO 2026

  • May 1, 2026

  • 2 min
TULIP: A New Approach to IOP Reduction

Low-power ultrasound biomodulation may offer a noninvasive, repeatable strategy to lower IOP without tissue destruction.

Emerging Technologies in Continuous IOP Monitoring

Wearable and implantable devices offer new data on pressure variability, though barriers to routine use persist.